The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.

J Bone Miner Res 2016 Apr 14;31(4):815-27. Epub 2015 Dec 14.

Myeloma Unit, Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy.

Multiple myeloma (MM) is characterized by severely imbalanced bone remodeling. In this study, we investigated the potential effect of proteasome inhibitors (PIs), a class of drugs known to stimulate bone formation, on the mechanisms involved in osteocyte death induced by MM cells. First, we performed a histological analysis of osteocyte viability on bone biopsies on a cohort of 37 MM patients with symptomatic disease. A significantly higher number of viable osteocytes was detected in patients treated with a bortezomib (BOR)-based regimen compared with those treated without BOR. Interestingly, both osteocyte autophagy and apoptosis were affected in vivo by BOR treatment. Thereafter, we checked the in vitro effect of BOR to understand the mechanisms whereby BOR maintains osteocyte viability in bone from MM patients. We found that osteocyte and preosteocyte autophagic death was triggered during coculturing with MM cells. Our evaluation was conducted by analyzing either autophagy markers microtubule-associated protein light chain 3 beta (LC3B) and SQSTM1/sequestome 1 (p62) levels, or the cell ultrastructure by transmission electron microscopy. PIs were found to increase the basal levels of LC3 expression in the osteocytes while blunting the myeloma-induced osteocyte death. PIs also reduced the autophagic death of osteocytes induced by high-dose dexamethasone (DEX) and potentiated the anabolic effect of PTH(1-34). Our data identify osteocyte autophagy as a new potential target in MM bone disease and support the use of PIs to maintain osteocyte viability and improve bone integrity in MM patients.

Download full-text PDF

Source
http://dx.doi.org/10.1002/jbmr.2741DOI Listing
April 2016
57 Reads

Publication Analysis

Top Keywords

osteocyte viability
16
osteocyte
9
autophagic death
8
viability bone
8
osteocyte death
8
proteasome inhibitors
8
osteocyte autophagy
8
multiple myeloma
8
maintains osteocyte
8
bone
6
patients
5
bone patients
4
dexamethasone dex
4
bor treatment
4
vivo bor
4
preosteocyte autophagic
4
osteocyte preosteocyte
4
patients osteocyte
4
treatment checked
4
checked vitro
4

References

(Supplied by CrossRef)
Pathogenesis of myeloma bone disease
Roodman et al.
Leukemia 2009
The amazing osteocyte
Bonewald et al.
J Bone Miner Res 2011
Do osteocytes contribute to bone mineral homeostasis
Teti et al.
Osteocytic osteolysis revisited. Bone 2009
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation
van Bezooijen et al.
Cytokine Growth Factor Rev 2005
Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip
Weinstein et al.
J Clin Endocrinol Metab 2000
The death of osteocytes via apoptosis accompanies estrogen withdrawal in human bone
Tomkinson et al.
J Clin Endocrinol Metab 1997

Similar Publications